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Abstracts A11
Diabetic patients with continuous coverage from January 2002 to December 2004 in 
a state Medicaid program, and who had an index prescription claim for ACEI/ARB 
in the ﬁrst six months of 2002 were included in the study. Adherence with ACEI/ARB 
therapy was measured using the proportion of days covered (PDC) during the 
12-month post-index period. Nonadherence was deﬁned as PDC < 0.8. The primary 
outcomes of interest were diabetes-related hospitalization and all-cause mortality in 
the follow-up period (end of post-index period to December 31, 2004). Multivariate 
regression analyses were performed to assess the independent effect of nonadherence 
with ACEI/ARB on outcome measures. RESULTS: 14,428 patients met our inclusion 
criteria. Among them, 75% were females and the mean age was 60.5 (±14.2) years. 
About 69% were nonadherent with prescribed ACEI/ARB therapy. During follow-up, 
10.9% patients had diabetes-related hospitalizations and 1.1% died for any reason. 
After controlling for baseline patient characteristics including age, gender, race, prior 
hospitalization, and comorbidities (Charlson comorbidity index), in comparison to 
adherent patients, the odds for diabetes-related hospital admission was 72.7% (OR: 
1.727; 95%CI: 1.508–1.976) higher for nonadherent patients. The odds for all-cause 
mortality were not statistically signiﬁcant between adherent and nonadherent patients 
(OR: 1.011; 95%CI: 0.721–1.419). Results of sensitivity analyses stratifying on 
patient age were consistent with our primary ﬁndings. CONCLUSIONS: The results 
suggest that nonadherence to ACEI/ARB is common among diabetic patients enrolled 
in a state Medicaid program. Nonadherence to ACEI/ARB appears to be associated 
with higher risks for diabetes-related hospitalization.
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OBJECTIVES: To investigate the association of multiple medication compliance with 
health care utilization. METHODS: We identiﬁed patients ≥40 years of age with a 
diagnosis of type II diabetes and comorbid cardiovascular disease (CVD) including 
hypertension, coronary artery disease, and heart failure from California Medicaid 
claim data between 2002 and 2004. Proportion of days covered ≥0.8 was used to 
assess medication compliance. Multivariate two-part models were used to determine 
health care utilization in 2004 across different medication compliance statuses after 
controlling for confounding factors. RESULTS: A total of 21,740 patients were 
analyzed. Only 18% of patients were compliant with both diabetes and CVD medica-
tions, 32% compliant with only diabetes medication, and 7% with only CVD medica-
tion. Adherence to both diabetes and CVD medications was signiﬁcantly associated 
with decreased number of emergency room (ER) visits (0.052 ± 0.011, p < 0.0001), 
decreased hospitalization (0.025 ± 0.004, p < 0.0001), increased number of outpatient 
visits (10.02 ± 0.67, p < 0.001) and increased number of prescription ﬁlls (35 ± 0.89, 
p < 0.0001). Mean covariate adjusted ER visits (0.26 ± 0.62) in patients who did not 
ﬁll appropriate medications or were noncompliant with medications were signiﬁcantly 
higher than those compliant with both diabetes and CVD medications (0.19 ± 0.42, 
p = 0.000), or those compliant with only diabetes medications (0.21 ± 0.46, p = 0.000). 
Mean adjusted number of hospitalizations in patients compliant with only CVD 
medication (0.11 ± 0.31, p = 0.01) was signiﬁcantly higher than those compliant with 
both diabetes and CVD medications (0.08 ± 0.22, p = 0.01) or compliant with only 
diabetes medication (0.08 ± 0.20, p = 0.001). CONCLUSIONS: Compliance with 
multiple medications was signiﬁcantly associated with a decrease in the number of ER 
visits and hospitalizations in a California Medicaid population with type II diabetes 
and comorbid CVD.
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OBJECTIVES: The association between perioperative blood pressure (BP) control and 
reduced risks of death and complications in cardiac surgery patients has been demon-
strated in the ECLIPSE (Evaluation of CLevidipine In the Perioperative Treatment of 
Hypertension Assessing Safety Events) trials. This study evaluated the relationship 
between perioperative BP control and the total costs of hospitalization and 30-day 
readmission in ECLIPSE patients undergoing coronary artery bypass grafting (CABG) 
or valve surgery. METHODS: Cost data were obtained from the Massachusetts Acute 
Hospital Case Mix Database for 2005–2007 for patients undergoing cardiac surgery 
and analyzed separately for patients who experienced death, myocardial infarction, 
stroke, bleeding, infections, renal failure, multiple complications, or none of these 
complications. These data were used to assign 2009 hospitalization costs to ECLIPSE 
patients by matching their complications and length of stay. BP control was deﬁned 
as area under the curve (AUC) capturing the magnitude and duration of systolic blood 
pressure excursions outside pre-speciﬁed ranges and expressed in units of mm Hg × 
minutes/hour. Smaller AUC values represent more precise BP control. The relationship 
between AUC and costs was examined using a log-normal model. Outcomes were 
evaluated for all patients, patients undergoing CABG, patients undergoing valve 
surgery, and patients with both procedures. RESULTS: Mean costs for patients in 
ECLIPSE were $52,941 and ranged from $47,349 for patients with CABG only to 
$79,442 for patients with CABG and valve surgery. After controlling for potential 
confounders, perioperative AUC below 10 was associated with 5.9% lower costs 
(95% conﬁdence interval of 0.9%-11.2%) with the largest reduction in patients 
undergoing CABG surgery only (7.8%). For the population with AUC above 10, 
reducing AUC to below 10 was predicted to reduce costs by $3080, ranging from 
$891-$4444 depending on the surgery group. CONCLUSIONS: Effective periopera-
tive BP control in patients undergoing cardiac surgery has a signiﬁcant impact on 
hospitalization costs.
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OBJECTIVES: This study examines whether valsartan initiation is associated with a 
post-initiation reduction in medical costs among hypertensive patients. METHODS: 
A retrospective interrupted time series design was used with a large, US national 
claims database for the period of 2004–2008. Hypertensive patients who initiated 
valsartan between the ages of 20 and 63, and had continuous enrollment for 
24-month pre- and 24-months post- valsartan initiation were selected. Patients’ 
monthly medical costs were calculated based on individual claims. To detect a post-
initiation reduction in the medical costs, interrupted time series models were devel-
oped with the following key covariates: valsartan initiation, initiation month, 
pre-initiation month, and post-initiation month. A similar time series model was used 
to forecast post-initiation medical costs for the same patients had they not initiated 
valsartan. The number of post-initiation months before the actual medical costs con-
verged with the forecasted medical costs was assessed as the time needed to reach the 
cost-offset point. RESULTS: Patients (N = 18,269) had mean age of 53 at the valsar-
tan initiation date, and 53% of them were female. The most common co-morbid con-
ditions were dyslipidemia (52%), diabetes (24%), hypertension with complications 
(17%), and ischemic heart disease (13%). The time series model estimated that 
medical costs were increasing about $10 per month (P < 0.01) prior to valsartan initi-
ation, and decreasing about $6 per month (P < 0.01) after the initiation. The actual 
medical cost reduction after valsartan initiation was statistically signiﬁcantly lower (P 
< 0.01) than the forecasted medical costs after the 2nd month. Similar trend was also 
observed in hypertension-related medical costs. CONCLUSIONS: Hypertension 
patients experienced increasing monthly medical cost prior to valsartan initiation. 
However, after initiation, there was a statistically signiﬁcant decrease in medical costs, 
which after only two months was signiﬁcantly lower than the forecasted costs of the 
same patients had they not initiated valsartan.
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OBJECTIVES: Observational data provide an opportunity to assess drug efﬁcacy in 
the real world. However, because treatment decisions may be based on prognosis, 
estimates of treatment effects obtained from observational data may suffer from 
“confounding by indication.” To address this concern, we used a grouped-treatment 
approach to determine the impact of choice of anticoagulant on length of hospital 
stay (LOS) and cost in patients undergoing percutaneous coronary intervention (PCI). 
METHODS: We analyzed the Premier Perspective Database for all patients aged ≥18 
years admitted to Premier hospitals with a diagnosis of ST-elevated myocardial infarc-
tion (STEMI) and ≥1 procedure code for PCI between Q12004 and Q12008 (N = 
71,296). We constructed individual-level models of LOS and cost, similar to those in 
a conventional multivariate analysis, except that each individual’s actual treatment 
variables were replaced with grouped-treatment variables (the proportion of patients 
receiving each treatment at the hospital/year in which treatment occurred). We used 
linear regression to assess the impact of the likelihood of treatment with bivalirudin 
or heparin ± a glycoprotein IIb/IIIa inhibitor on LOS and cost (in 2008$), controlling 
for other treatments (including stent use, other drug use, CABG); patient demograph-
ics, diagnosis, insurance status, physician specialty; and hospital region, size, teaching 
status. We calculated conﬁdence intervals allowing for the clustering of errors at the 
hospital/year level. RESULTS: Bivalirudin treatment was associated with a reduction 
in LOS of 0.917 days (95% CI: −1.393, −0.441) and a reduction in cost of $4,554 
(95% CI: −7,936, −1,172) compared to heparin+GPI. CONCLUSIONS: Increasing 
the proportion of a hospital’s patients treated with bivalirudin was associated with a 
signiﬁcant reduction in LOS and cost, compared to heparin+GPI. The estimated effects 
of bivalirudin from a grouped-treatment model were signiﬁcantly larger than those 
from a conventional individual-level analysis, suggesting that confounding by indica-
tion may be important in this context.
